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Metabolism of Glycitein (7,4′-Dihydroxy-6-methoxy-isoflavone)
by Human Gut Microflora
ANDREAN L. SIMONS, MATHIEU RENOUF, SUZANNE HENDRICH, AND
PATRICIA A. MURPHY*
Department of Food Science and Human Nutrition, 2312 Food Sciences Building,
Iowa State University, Ames, Iowa 50011
Gut microbial disappearance and metabolism of the soy isoflavone glycitein, 7,4′-dihydroxy-6-
methoxyisoflavone, were investigated by incubating glycitein anaerobically with feces from 12 human
subjects. The subjects’ ages ranged from 24 to 53 years with a body mass index (BMI) of 20.9-25.8
kg/m2 (mean BMI ) 24.0 ( 1.1 kg/m2). Glycitein disappearance followed an apparent first-order rate
loss. Fecal glycitein disappearance rates for the subjects segregated into three different groups
described as high (k ) 0.67 ( 0.14/h), moderate (k ) 0.34 ( 0.04/h), and low (k ) 0.15 ( 0.07/h)
glycitein degraders (p < 0.0001). There was no dose effect on the disappearance rates for each
subject from 10 to 250 íM glycitein (average k ) 0.32 ( 0.03/h, p > 0.05). Four putative glycitein
metabolites, characterized by liquid chromatography-mass spectrometry (electrospray ionization using
positive ionization mode), were dihydroglycitein, dihydro-6,7,4′-trihydroxyisoflavone, and 5′-O-methyl-
O-desmethylangolensin. Two subjects produced a metabolite tentatively identified as 6-O-methyl-
equol, and one subject produced daidzein as an additional metabolite of glycitein. These results
show that glycitein is metabolized by human gut microorganisms and may follow metabolic pathways
similar to other soy isoflavones.
KEYWORDS: Glycitein; isoflavone; microbial metabolism; dihydroglycitein; dihydro-6,7,4′-trihydroxy-
isoflavone
INTRODUCTION
Isoflavones are a subclass belonging to a larger group of
polyphenolic compounds called flavonoids. Isoflavones mainly
occur in plants of the Leguminosae family (1). Soybeans and
soybean-derived foods are the main sources of the isoflavones
genistein (5,7,4′-trihydroxyisoflavone), daidzein (7,4′-dihydroxy-
isoflavone), and glycitein (7,4′-dihydroxy-6-methoxyisoflavone)
where the total isoflavone concentration can reach up to 2 g
per kg fresh weight (2). Glycitein comprises less than 10% of
the total isoflavone amount in soybeans and soybean foods but
comprises about 50% of the isoflavone mass in soy germ (3).
The three soy isoflavones are hydroxylated in the 7- and 4′-
positions of the isoflavone skeleton (Figure 1), which makes
them structurally similar to â-estradiol (4). Apparently, because
of this similarity, isoflavones are weakly estrogenic and bind
to estrogen receptors (4). Glycitein was more estrogenic in a
mouse uterine growth assay than was genistein, when fed in
equal amounts (5). Epidemiological studies have reported
beneficial relationships between isoflavone intake and decreased
risk of chronic diseases, although more recent studies have not
observed these relationships (6-9). Isoflavones have been
proposed to decrease the risk of coronary heart disease, certain
types of cancers (10, 11), and osteoporosis (12) by a variety of
biological functions and mechanisms.
Isoflavones are found as both glucosides and aglucons in soy
foods (13). Oral ingestion of isoflavone glucosides leads to their
hydrolysis to aglucons in the small intestine by bacterial
â-glucosidase activity and â-glucosidases in gastrointestinal
mucosal cells (14). The free aglucons resulting from hydrolysis
can be absorbed, rapidly glucuronidated, and undergo first pass
hepatic metabolism (15) or be further metabolized by the gut
microflora. Antibiotic administration was shown to decrease the
production of isoflavone metabolites in humans (16). Experi-
ments with germ-free rats revealed that isoflavone metabolites
were not excreted in the urine (17). Understanding the metabo-
lism of isoflavones in the gut is important because this process
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Figure 1. Soy isoflavone structures, substitution patterns, and numbering
system.
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may affect their bioavailability and their overall absorption and
biological activities in vivo (18).
The anaerobic bacterial metabolism of genistein and daidzein
by gut microflora has been studied extensively. Genistein
metabolites resulting from anaerobic metabolism in the human
gut have been identified as dihydrogenistein (19-23), 6′-
hydroxy-O-desmethylangolensin (6′-OH-ODMA) (20-23), 4-hy-
droxyphenyl-2-propionic acid (22, 23), and phloroglucinol (22).
Anaerobic bacterial metabolism of daidzein resulted in dihy-
drodaidzein (19-21), O-desmethylangolensin (24, 25), equol
(19, 25, 26), and cis-4-hydroxy-equol (20, 21). In contrast,
glycitein microbial metabolites have not been well-characterized
in vitro. Glycitein comprises less than 10% of the total
isoflavone amount in soybeans and soybean foods and may be
the reason that its metabolism has not been well-studied.
However, glycitein comprises about 50% of the isoflavone mass
in soy germ (3). Glycitein was demethoxylated in vitro by
Eubacterium limosum to 6,7,4′-trihydroxyisoflavone (27). Re-
cently, glycitein metabolites, dihydroglycitein, 5′-O-methyl-O-
desmethylangolensin, and 6-O-methyl-equol have been isolated
and characterized in human urine (21).
Earlier studies by our group showed that the rate of disap-
pearance of glycitein was significantly slower than that of
genistein (p < 0.0001) in an in vitro fecal fermentation system
(18), and the human bioavailability of glycitein was significantly
greater than genistein (28). The aim of this study was to further
characterize glycitein metabolism in humans by investigating
the kinetics and variability of the apparent fecal degradation
reaction and the metabolites of glycitein using an in vitro fecal
fermentation system.
MATERIALS AND METHODS
Chemicals. Glycitein was synthesized according to Lang’at-Thoruwa
et al. (29). Daidzein and 2,4,4′-trihydroxydeoxybenzoin were synthe-
sized using the method of Song et al. (3). Genistein was synthesized
according to a modification of Chang et al. (30). The purities of
glycitein, genistein, daidzein, and 2,4,4′-trihydroxydeoxybenzoin were
99+%. 6,7,4′-Trihydroxyisoflavone was purchased from Indofine
Chemical Co., Inc. (Hillsborough, NJ). Dihydrodaidzein, dihydro-
genistein, equol, and O-desmethylangolensin were purchased from
Plantech U.K. (Reading, England). All other chemicals including high-
performance liquid chromatography (HPLC) grade acetonitrile, metha-
nol, acetic acid, and dimethyl sulfoxide were purchased from Fisher
Scientific (Fairlawn, NJ). All aqueous solutions were prepared using
Milli-Q system (Millipore Co., Bedford, MA) HPLC grade water (MQ
water).
Subject Protocol. Four men and eight women volunteered from Iowa
State University and the surrounding Ames area. The subjects were in
good health and not taking any medication. The subjects’ ages ranged
from 24 to 53 years with a body mass index (BMI) of 20.9-25.8 kg/
m2 (mean BMI ) 24.0 ( 1.1 kg/m2). The ethnicities of the subjects
included six Caucasians, three African Americans, one Chinese
immigrant, one Asian-Indian, and one Latino. Subjects were given
written instructions about soy-containing foods to avoid for 1 week
before collecting one fresh fecal sample in sealed sterile containers
(Sage Products Inc., Crystal Lake, IL). Approval of the study design
was obtained from the Iowa State University Human Subjects Research
Committee in 2003.
Isoflavone Fermentation and Extraction. In vitro fecal fermenta-
tion systems and the isoflavone extraction from the fermentation systems
were carried out according to Simons et al. (31) with the following
changes. Daidzein, glycitein, and genistein were added to a fecal
suspension at 100 íM. Glycitein dose response was investigated by
adding glycitein to fecal suspensions for final concentrations of 10,
50, 75, 100, and 250 íM glycitein. The negative control consisted of
the fecal suspension without isoflavones. The positive control consisted
of brain heart infusion media and 250 íM daidzein, genistein, and
glycitein without the fecal suspension. All isoflavone fermentations were
carried out in duplicate.
HPLC Analysis. The HPLC system consisted of a Hewlett-Packard
1050 Series. Twenty microliters of isoflavone extract was injected onto
a reversed phase 250 mm  4.6 mm, 5 ím, C18 AM 303 column
(YMC Co. Ltd., Wilmington, NC). The mobile phase consisted of 0.1%
glacial acetic acid in water (A) and acetonitrile (B). Solvent B was
increased from 30 to 50% in 14 min, increased to 100% in 5 min, and
recycled back to 30% in 1 min. The flow rate was 1 mL/min. The
wavelengths used for the detection of isoflavone and metabolite peaks
and for the preparation of isoflavone standard curves were 254 and
280 nm. Chem station3D software (Hewlett-Packard Co., Scientific
Instruments Division, Palo Alto, CA) was used to integrate the peak
area responses and to evaluate the ultraviolet absorbance spectra.
Mass Spectrometry Analysis. Analyses of glycitein metabolites
were carried out using a Shimadzu 2010 LC-MS system (Kyoto, Japan)
consisting of a Shimadzu 2010 liquid chromatograph with a dual
wavelength photodiode array detector in series between the chromato-
graph and a Q-array-Octapole-Quadrupole mass analyzer. Detection
of metabolites was performed using electrospray ionization (ESI) in
the positive ion mode. The mobile phase for sample separation was
performed under the same conditions as used for HPLC analysis except
that the flow rate was 0.2 mL/min. The injection volume was 20 íL.
Samples were introduced into the electrospray interface through an
untreated fused silica capillary. A nitrogen gas flow of 4.5 L/min was
used as the nebulizing and auxiliary gas for the mass spectrometer.
The parameters applied to MS were as follows: block temperature,
200 °C; desolvation temperature, 400 °C; capillary voltage, 3.8 kV;
and cone voltage, 20 V. The mass spectrometer was tuned and calibrated
for the range of m/z 100-300. Daidzein, glycitein, 6,7,4′-trihydroxy-
flavone, and O-desmethylangolensin were dissolved in 100% methanol
at 25 ímol/L and analyzed to obtain authentic mass spectra prior to
sample analysis.
Data Analysis and Statistics. The rate of disappearance of isofla-
vones in fecal suspensions was estimated by plotting ln(% remaining
isoflavone) vs time, and the negative of the slope was the apparent
first-order degradation rate constant. An internal standard curve
employing 2,4,4′-trihydroxydeoxybenzoin was used to estimate the
concentration of isoflavones in the fecal suspensions. Zero time
concentrations were corrected for recovery for each subject. Statistical
evaluation of degradation rate differences was performed using the SAS
system (version 8.1, SAS Institute, Cary, NC). Differences between
the overall and the individual degradation rates of isoflavones were
estimated using one-way analysis of variance. Isoflavone degradation
phenotypes were identified using average linkage cluster analysis (32).
The statistical significance of all analyses was set at R ) 0.05.
RESULTS AND DISCUSSION
The glycitein concentrations studied in our fermentation
systems represented probable doses of isoflavones in the human
gut after ingestion of soy-containing foods (Figure 2). A plot
Figure 2. In vitro average human microbial degradation rates of glycitein
at 10, 50, 75, 100, and 250 íM. Error bars represent standard deviation
from the mean, n ) 12.
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of the natural log of the percentage remaining for each
isoflavone against time resulted in a straight line for all subjects,
with correlation coefficients ranging from 0.75 to 0.99. These
findings suggest that isoflavone degradation by gut microflora
follows apparent first-order kinetics, which supports other
investigations reporting isoflavone degradation kinetic data (18,
33). There were no significant differences in the average
degradation rate for each glycitein dose across all subjects with
an average k ) 0.30 ( 0.21/h, p > 0.05 (Figure 2).
Cluster analysis allowed us to determine if any groupings of
similar isoflavone degradation rates occurred in these subjects.
Three different degradation rate groupings were discerned for
glycitein: high (k ) 0.67 ( 0.14/h), moderate (k ) 0.34 (
0.04/h), and low (k ) 0.15 ( 0.07/h) glycitein degraders (p <
0.0001; Figure 3). These phenotypes were observed for
genistein and daidzein degradation rates as well (Table 1). These
data were similar to that reported by Hendrich et al. (34), who
found three isoflavone degradation phenotypes (high, moderate,
and low) from nine men and 11 women.
The glycitein degradation rate, with an average k ) 0.30 (
0.21/h, was significantly lower than genistein with an average
k ) 0.43 ( 0.44/h, p ) 0.02, but not different from daidzein
with an average k ) 0.16 ( 0.17/h, p ) 0.07. We believe that
this difference is due to structural differences between the three
isoflavones. It has been proposed that the hydroxyl group in
the 5th position on the A ring of the flavonoid structure is
responsible for the rapid degradation of genistein by gut
microflora (18, 35). We have shown in related studies that
flavonoids with hydroxyl groups in the 5-, 7-, and 4′-positions
were significantly more rapidly degraded in human fecal
incubations than were flavonoids not possessing all of these
hydroxyls (31).
Phenotypic trends were observed in all of the subjects (Table
1). Subjects 9, 13, and 26 had moderate and high degradation
phenotypes and subjects 5, 8, 17, and 18 had low degradation
phenotypes for all three isoflavones. We speculated that these
differences in degradation phenotypes were because of distinct
differences in individual gut bacterial populations. Our prelimi-
nary studies have shown different bacterial DNA profiles of
rapid isoflavone degraders as compared with subjects of slow
degradation phenotype using polymerase chain reaction-
denaturing gradient gel electrophoresis (36). Different fecal
bacterial species were identified in high glycitein degraders as
compared with high genistein degraders. Subjects with low in
vitro isoflavone degradation phenotypes may experience higher
isoflavone bioavailabilty in vivo, as compared to subjects with
high isoflavone degradation phenotypes. Zheng et al. (37) have
shown that Asian women with low genistein degradation
phenotypes experienced greater genistein bioavailability as
compared with Asian subjects with high genistein degradation
phenotypes. The overall average glycitein degradation rate
(average k ) 0.30 ( 0.21/h) did not change when fermented
with genistein and daidzein (average k ) 0.23 ( 0.19/h, p )
0.72). These data suggest that the isoflavones may not compete
with each other for metabolism by the gut microflora.
We hypothesized that the main glycitein metabolite should
be dihydroglycitein based on reports identifying dihydrodaidzein
and dihydrogenistein as the main metabolites of daidzein and
genistein, respectively (19, 20). In vitro metabolism studies by
Hur et al. (27) reported that glycitein was metabolized to 6,7,4′-
trihydroxyisoflavone by E. limosum. E. limosum is able to
O-demethylate methoxyl derivatives of benzoic acid (38) and
is found in the human digestive tract (39). On the basis of the
data in these studies, we predicted that 6,7,4′-trihydroxyisofla-
vone would be one of the metabolites of glycitein.
HPLC chromatograms were analyzed for the formation of
new peaks in the fecal fermentation suspensions over the 24 h
period. In two subjects, intact glycitein levels remained the same
over the 24 h period and there was no evidence of new
chromatographic peaks. For the other 10 subjects, two new peaks
(peaks 1 and 4) appeared after 6 h of incubation at retention
times 14.5 and 19.9 min, respectively (Figure 4A). Two
additional new peaks (peaks 2 and 3) appeared after 24 h of
incubation with retention times of 17.5 and 17.7 min, respec-
tively (Figure 4A). Peak 2 was observed in only two of the 10
subjects producing metabolites. One subject showed an ad-
ditional new peak at 15.9 min (peak 5) (Figure 4B). None of
the other chromatogram peaks were associated with glycitein
metabolism because they appeared in negative controls.
The UV spectra and retention time of peak 1 from HPLC
analysis were identical to the chemically synthesized reference
standard, 6,7,4′-trihydroxyisoflavone. However, mass spectro-
metric analysis using positive ESI (M + H+) revealed that the
molecular weights of peak 1 and 6,7,4′-trihydroxyisoflavone
were different m/z 273 and 271, respectively. On the basis of
these data, the identity of peak 1 was tentatively given as
dihydro-6,7,4′-trihydoxyisoflavone. The UV spectra and reten-
Figure 3. Statistical cluster analysis of subjects’ glycitein degradation rates.
Subjects segregated into high (n ) 2), moderate (n ) 4), and low (n )
6) glycitein degraders (p < 0.0001). All degradation rates were determined
from duplicate fermentation experiments.
Table 1. Cluster Analysis of Subjects’ Isoflavone Degradation Ratesa
degradation rate (k/h)b subject IDc
isoflavone high moderate low high moderate low
glycitein 0.67 ± 0.14 0.34 ± 0.04 0.15 ± 0.07 13, 9 26, 3, 11, 2 6, 8, 18, 17, 4, 5
daidzein 0.34 ± 0.04 0.17 ± 0.04 0.03 ± 0.02 9, 26 6, 13, 2, 3, 11, 4 8, 5, 18, 17
genistein 1.54d 0.77 ± 0.01 0.17 ± 0.08 13 26, 2, 3 8, 9, 5, 17, 11, 4, 18, 6
a Degradation phenotypes of subjects. Subjects separated into three significantly different groups for each isoflavone, named high, moderate, and low degraders (p <
0.0001). b Degradation rates expressed as averages ± standard deviation of the mean. c Whole numbers shown are subjects’ identification number. d Standard deviation
could not be determined from a measurement of only one subject’s degradation rate.
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tion time of peak 5 and daidzein were identical. MS analysis
confirmed that peak 5 was daidzein with a molecular weight
(M + H)+ of 255.
Peaks 2-4 were more hydrophobic than glycitein (Figure
4A,B). The UV spectra of peaks 2-4 were similar to the
daidzein microbial metabolites, equol, O-desmethylangolensin,
and dihydrodaidzein, respectively. MS analysis for these three
peaks showed molecular weights (M + H)+ of m/z 271, 289,
and 287, respectively, which would tentatively match 6-meth-
oxy-equol, 5′-methoxy-O-desmethylangolensin, and dihydro-
glycitein, respectively, based on the MS and UV absorbance.
Glycitein is similar to daidzein structurally with exception
of the methoxyl group at the 6-position. We expected to identify
metabolites that were similar to the daidzein metabolites
dihydrodaidzein, equol, and O-desmethylangolensin (19-21).
We detected dihydroglycitein in the fecal incubations, but the
major metabolite appearing in all metabolite-producing subjects
was dihydro-6,7,4′-trihydroxyisoflavone at 6 h after incubation.
These observations suggest that the first step in glycitein
metabolism is reduction to dihydroglycitein and then O-
demethylation to dihydro-6,7,4′-trihydroxyisoflavone. However,
glycitein may first be O-demethylated to 6,7,4′-trihydroxyisofla-
vone and then further reduced to dihydro-6,7,4′-trihydroxy-
isoflavone. We did not detect 6,7,4′-trihydroxyisoflavone in our
incubation mixtures suggesting that the step to dihydro-6,7,4′-
trihydroxyisoflavone is either extremely rapid or that this route
was not viable. The O-demethylation pathway of glycitein to
6,7,4′-trihydroxyisoflavone would be similar to the microbial
metabolic pathways of formononetin (7-hydroxy-4′-methoxy-
isoflavone) and biochanin A (5,7-dihydroxy-4′-methoxyisofla-
vone) (27).
Heinonen et al. (21) identified dihydrodaidzein, dihydro-
genistein, and dihydroglycitein in the urine of six human subjects
fed three soy bars, equivalent to a daily intake of 48.4, 40.2,
and 4.1 mg of daidzein, genistein, and glycitein, respectively,
for 2 weeks. These data imply that daidzein, genistein, and
glycitein were metabolized to their respective dihydroisoflavones
and absorbed across the intestinal wall. However, Bowey et al.
(17) observed that dihydrogenistein and dihydrodaidzein were
produced in the urine of germ-free rats. They concluded that
dihydrogenistein, dihydrodaidzein, and dihydroglycitein are not
products of microbial metabolism, which conflicts our observa-
tion of dihydroglycitein as a microbial metabolite of glycitein.
Because previous studies have reported the microbial conversion
of daidzein and genistein to dihydrodaidzein and dihydro-
genistein, respectively (19-23), we propose that dihydrogly-
citein and other dihydroisoflavones are produced by both
intestinal bacteria and gut mucosal enzymes.
The metabolite, 5′-OMe-O-desmethylangolensin, most likely
results from C ring cleavage of dihydroglycitein, consistent with
bacterial C ring cleavage observations of daidzein and genistein
(16, 17). Heinonen et al. (21) identified 5′-OH-O-desmethyl-
angolensin in addition to 5′-OMe-O-desmethylangolensin in
human urine, which suggested direct C ring cleavage of dihydro-
Figure 4. HPLC chromatograms of fecal fermentation extracts after 24 h of incubation with 250 ímol glycitein in two subjects (A and B). Numbers
shown are for metabolite peaks. All other peaks were not associated with glycitein metabolism and appeared in negative controls. The tentative identity
of peaks 1−5 is given in the text.
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6,7,4′-trihydroxyisoflavone or demethylation of 5′-OMe-O-
desmethylangolensin. We did not detect 5′-OH-O-desmethyl-
angolensin in our fecal fermentation mixtures over the 24 h
incubation period.
Production of daidzein from glycitein would result from direct
demethoxylation of glycitein at the 6-position. However, only
one subject produced daidzein in this study. Additionally,
bioavailability studies in our laboratory have shown that daidzein
was produced in only one out of 10 hamsters that were fed
purified glycitein (unpublished data). Setchell et al. (40) reported
that humans fed glycitin (glycitein-7-O-â-D-glucopyranose)
showed only minute concentrations of daidzein in plasma. Taken
together, these results suggest that demethoxylation of glycitein
may not be a major pathway of metabolism in humans and
hamsters.
We observed the in vitro degradation of daidzein for each
subject and did not observe any equol production. However,
our in vitro fecal fermentation models are poor indicators of
equol-producer phenotypes, because apparently, equol is only
produced in response to chronic soy ingestion over a period of
at least 3 days (41, 42). Therefore, we may have had equol
producers among the 12 subjects. We proposed that 6-methoxy-
equol and 6-hydroxy-equol would be possible metabolites of
glycitein, and we were able to identify 6-methoxy-equol in two
subjects.
We realize that there were some limitations in our glycitein
metabolite identification process. The metabolites were identified
based on interpretation of the HPLC, MS, and UV data since
we did not have authentic reference standards for direct
comparisons. Nevertheless, the metabolites identified in these
studies have allowed us to propose several microbial pathways
for glycitein shown in Figure 5. The major pathways of glycitein
microbial metabolism are reduction to dihydroglycitein (7,4′-
dihydroxy-6-methoxy-isoflavanone), followed by demethylation
to produce dihydro-6,7,4′-trihydroxyisoflavone (6,7,4′-trihy-
droxyisoflavanone) or, alternatively, C ring cleavage of dihy-
droglycitein to produce 5′-methoxy-O-desmethylangolensin.
Minor pathways include direct demethoxylation of glycitein to
daidzein (7,4′-dihydroxyisoflavone) and reduction of dihydro-
glycitein to 6-OMe-equol (7,4′-dihydroxy-6-methoxy-isoflavan).
The estrogenic activity of isoflavones may be affected by
gut microbial metabolism. For example, equol, a metabolite of
daidzein, has been reported to be more estrogenic than daidzein
(43, 44). p-Ethylphenol, a metabolite of genistein, has no
estrogenic activity even though genistein possesses estrogenic
activity and other biological effects (45). Song et al. (5) have
shown that glycitein possessed a lower in vitro estrogen receptor-
binding affinity as compared to genistein but gave a higher
estrogenic response in an in vivo mouse uterine enlargement
assay. This higher estrogenic response probably resulted from
the higher bioavailability of glycitein as compared to genistein
or the formation of glycitein metabolites in the in vivo assays
that possess higher estrogenic potencies than the parent com-
pound. 6,7,4′-Trihydroxyisoflavone has been shown to exhibit
weak estrogenic activity and binds the estrogen receptor â with
little or no affinity (45, 46). It would be interesting to determine
the estrogenic properties of the other glycitein metabolites. The
gut microflora play a significant role in the bioavailability of
isoflavones (18, 28, 37, 47). Plasma daidzein and genistein
concentrations were negatively correlated with the daidzein and
genistein microbial degradation rate constants, respectively (37),
suggesting that increased isoflavone intestinal microbial deg-
radation reduced the amount of intact isoflavones appearing in
plasma after absorption. Additionally, daidzein and glycitein
were more bioavailable than genistein, as reflected in urinary
excretion as a percentage of ingested dose, because daidzein
and glycitein were degraded at a much slower rate as compared
to genistein (28).
In this study, we have found that glycitein was metabolized
according to first order kinetics by human gut microflora but
at a slower rate as compared to genistein. We found that there
was significant interindividual variation in glycitein degradation,
but the degradation rates were segregated into three different
groups (p < 0.0001). We tentatively identified three major
glycitein metabolites (dihydroglycitein, dihydro-6,7,4′-trihy-
droxyisoflavone, and 5′-OMe-O-desmethylangolensin) in 10 of
12 subjects, while two subjects failed to produce any metabo-
lites. Of the 10 metabolite producers, two subjects apparently
produced 6-OMe-equol and one subject produced daidzein. The
biological significance and exact identity of the glycitein
metabolites have yet to be determined.
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